Royalty Pharma Announces Expansion of Leadership Team
December 21 2020 - 7:12AM
Royalty Pharma plc (Nasdaq: RPRX) today announced an expansion of
its leadership team:
- Jim
Reddoch, PhD will assume increased responsibilities with a
new role of Chief Scientific Officer, which is in addition to his
position as Co-Head of Research & Investments.
- Marshall
Urist, MD, PhD has been promoted to Executive Vice
President and Co-Head of Research & Investments.
- Sandy
Balkin, PhD will join Royalty Pharma as Senior Vice
President, Strategy and Analytics.
Pablo Legorreta, Royalty Pharma’s founder and
Chief Executive Officer, commented “We are thrilled to expand Jim’s
role and promote Marshall to co-head the Research & Investments
group. This team is rapidly growing and with our increased
transaction activity, these new roles expand our bandwidth to
better assess and execute on the many opportunities to continue to
grow our business.”
“We are in a golden age of biotechnology
innovation. With the creation of the Chief Scientific Officer role
and the implementation of a new Strategy and Analytics group, we
plan to increase our use of data and analytics. Sandy is uniquely
positioned to bridge the worlds of data and biopharma innovation,
adding a new dimension to Royalty Pharma’s analytical
capabilities.”
In his role as Executive Vice President,
Research & Investments, Jim Reddoch has led the team at Royalty
Pharma that focuses on sourcing and analyzing new investment
opportunities and partnerships for over 12 years. In his capacity
as Chief Scientific Officer, he will continue to deepen the team’s
knowledge base and will work with Sandy to build out a newly
created Strategy and Analytics function which will further expand
Royalty Pharma’s rigorous approach to mapping out and vetting
opportunities to fund innovation in life sciences.
Marshall Urist has sourced and analyzed numerous
royalty acquisitions as Senior Vice President, Research &
Investments since joining Royalty Pharma in 2013. As co-head of the
Research & Investments group, he will provide leadership and
forward-thinking as Royalty Pharma’s opportunities to partner with
life science innovators expands. Pablo Legorreta remarked,
“Marshall’s medical and scientific experience will provide unique
direction to the Research & Investments group.”
Sandy Balkin joins Royalty Pharma from Truist
Securities where he was head of data strategy and data science,
setting priorities for the bank and collaborating with research
analysts on novel projects. Previously, he was head of integrated
insights and platforms at Sanofi. He has also held leadership
positions at Pfizer and Boehringer Ingelheim, with an emphasis on
data and analytics. Sandy has a PhD in business administration with
a focus on statistics from Penn State.
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest
buyer of biopharmaceutical royalties and a leading funder of
innovation across the biopharmaceutical industry, collaborating
with innovators from academic institutions, research hospitals and
not-for-profits through small and mid-cap biotechnology companies
to leading global pharmaceutical companies. Royalty Pharma has
assembled a portfolio of royalties which entitles it to payments
based directly on the top-line sales of many of the industry’s
leading therapies. Royalty Pharma funds innovation in the
biopharmaceutical industry both directly and indirectly - directly
when it partners with companies to co-fund late-stage clinical
trials and new product launches in exchange for future royalties,
and indirectly when it acquires existing royalties from the
original innovators. Royalty Pharma’s current portfolio includes
royalties on more than 45 commercial products, including AbbVie and
J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s
Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’
Promacta, and Vertex’s Kalydeco, Symdeko, Orkambi and Trikafta, and
four development-stage product candidates. For more information,
visit www.royaltypharma.com.
Royalty Pharma plc’s Forward-Looking
Statements
The information set forth herein does not
purport to be complete or to contain all of the information you may
desire. Statements contained herein are made as of the date of this
document unless stated otherwise, and neither the delivery of this
document at any time, nor any sale of securities, shall under any
circumstances create an implication that the information contained
herein is correct as of any time after such date or that
information will be updated or revised to reflect information that
subsequently becomes available or changes occurring after the date
hereof. This document contains statements that constitute
“forward-looking statements” as that term is defined in the United
States Private Securities Litigation Reform Act of 1995, including
statements that express the company’s opinions, expectations,
beliefs, plans, objectives, assumptions or projections regarding
future events or future results, in contrast with statements that
reflect historical facts. Examples include discussion of Royalty
Pharma’s strategies, financing plans, growth opportunities and
market growth. In some cases, you can identify such forward-looking
statements by terminology such as “anticipate,” “intend,”
“believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,”
“will,” “would,” “could” or “should,” the negative of these terms
or similar expressions. Forward-looking statements are based on
management’s current beliefs and assumptions and on information
currently available to the company. However, these forward-looking
statements are not a guarantee of Royalty Pharma’s performance, and
you should not place undue reliance on such statements.
Forward-looking statements are subject to many risks, uncertainties
and other variable circumstances, and other factors. Such risks and
uncertainties may cause the statements to be inaccurate and readers
are cautioned not to place undue reliance on such statements. Many
of these risks are outside of Royalty Pharma’s control and could
cause its actual results to differ materially from those it thought
would occur. The forward-looking statements included in this
document are made only as of the date hereof. Royalty Pharma does
not undertake, and specifically declines, any obligation to update
any such statements or to publicly announce the results of any
revisions to any such statements to reflect future events or
developments, except as required by law. Certain information
contained in this document relates to or is based on studies,
publications, surveys and other data obtained from third-party
sources and Royalty Pharma’s own internal estimates and research.
While Royalty Pharma believes these third-party sources to be
reliable as of the date of this document, it has not independently
verified, and makes no representation as to the adequacy, fairness,
accuracy or completeness of, any information obtained from
third-party sources. In addition, all of the market data included
in this document involves a number of assumptions and limitations,
and there can be no guarantee as to the accuracy or reliability of
such assumptions. Finally, while the company believes its own
internal research is reliable, such research has not been verified
by any independent source. For further information, please
reference Royalty Pharma’s reports and documents filed with the
U.S. Securities and Exchange Commission (“SEC”) by visiting EDGAR
on the SEC’s website at www.sec.gov.
Royalty Pharma Investor Relations and
Communications+1 (212) 883-2295ir@royaltypharma.com
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Apr 2024 to May 2024
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From May 2023 to May 2024